Wednesday, April 11, 2012
Omeros Corp., of Seattle, said it started patient enrollment in its second Phase III trial of PharmacoSurgery candidate OMS302 in intraocular lens replacement (ILR) surgery. The product is designed to be added to standard irrigation solution used during ILR procedures to maintain intraoperative mydriasis and reduce postoperative pain. About 400 patients undergoing cataract surgery or refractive lens exchange will be recruited, with data expected later this year. In the first Phase III study, the product hit statistical significance, showing superiority over placebo on both endpoints (p < 0.00001).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.